Matthew Winton - 31 Mar 2025 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Role
COO
Signature
/s/ Sanjay Subramanian, as attorney-in-fact for Matthew Winton
Issuer symbol
INZY
Transactions as of
31 Mar 2025
Net transactions value
+$1,917
Form type
4
Filing time
02 Apr 2025, 16:29:22 UTC
Previous filing
17 Mar 2025
Next filing
27 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INZY Common Stock Award $1,917 +2,490 +51% $0.7700 7,388 31 Mar 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of October 1, 2024 through March 31, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on March 31, 2025, the last trading day of the purchase period.